🇺🇸 FDA
Patent

US 10292979

Methods of treating cancer patients with farnesyltransferase inhibitors

granted A61KA61K31/4709A61K45/06

Quick answer

US patent 10292979 (Methods of treating cancer patients with farnesyltransferase inhibitors) held by Kura Oncology, Inc. expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Kura Oncology, Inc.
Grant date
Tue May 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/4709, A61K45/06, A61P, A61P35/00